Trials / Completed
CompletedNCT03710707
Study to Evaluate DNL201 in Subjects With Parkinson's Disease
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Denali Therapeutics Inc. · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DNL201 | Oral repeating dose |
| DRUG | Placebo | Oral repeating dose |
Timeline
- Start date
- 2018-12-04
- Primary completion
- 2019-12-06
- Completion
- 2019-12-06
- First posted
- 2018-10-18
- Last updated
- 2020-01-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03710707. Inclusion in this directory is not an endorsement.